There was a lot of movement in the drug policy space late in 2025.
CMS announced a new drug payment model and touted $12 billion in savings from 2024 under the drug price negotiation program under the IRA. And, the Trump administration made deals with major pharmaceutical companies Novo Nordisk, Eli Lilly, and Pfizer over the price of GLP-1 weight-loss drugs.
Joey Mattingly from the University of Utah College of Pharmacy will join Health Affairs’ Laura Tollen to get Insiders up to speed on the latest drug policy developments and what to expect later in 2026.
Date: January 21, 2026
Time: 1:30 pm – 2 pm ET
